- Home
- PCRX vs LDP Comparison
PCRX vs LDP Comparison
Compare PCRX & LDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- LDP
- Stock Information
- Founded
- PCRX 2006
- LDP 2012
- Country
- PCRX United States
- LDP United States
- Employees
- PCRX N/A
- LDP N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- LDP Finance Companies
- Sector
- PCRX Health Care
- LDP Finance
- Exchange
- PCRX Nasdaq
- LDP Nasdaq
- Market Cap
- PCRX 1.2B
- LDP 556.9M
- IPO Year
- PCRX 2011
- LDP N/A
- Fundamental
- Price
- PCRX $23.31
- LDP $21.27
- Analyst Decision
- PCRX Buy
- LDP
- Analyst Count
- PCRX 8
- LDP 0
- Target Price
- PCRX $28.38
- LDP N/A
- AVG Volume (30 Days)
- PCRX 537.5K
- LDP 102.5K
- Earning Date
- PCRX 07-29-2025
- LDP 01-01-0001
- Dividend Yield
- PCRX N/A
- LDP 7.91%
- EPS Growth
- PCRX N/A
- LDP N/A
- EPS
- PCRX N/A
- LDP N/A
- Revenue
- PCRX $702,772,000.00
- LDP N/A
- Revenue This Year
- PCRX $7.54
- LDP N/A
- Revenue Next Year
- PCRX $10.78
- LDP N/A
- P/E Ratio
- PCRX N/A
- LDP N/A
- Revenue Growth
- PCRX 3.08
- LDP N/A
- 52 Week Low
- PCRX $11.16
- LDP $16.16
- 52 Week High
- PCRX $27.64
- LDP $20.30
- Technical
- Relative Strength Index (RSI)
- PCRX 37.20
- LDP 75.02
- Support Level
- PCRX $22.82
- LDP $21.01
- Resistance Level
- PCRX $23.83
- LDP $21.25
- Average True Range (ATR)
- PCRX 0.67
- LDP 0.13
- MACD
- PCRX -0.05
- LDP 0.02
- Stochastic Oscillator
- PCRX 20.73
- LDP 98.57
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.